Lenvatinib is an oral tyrosine kinase inhibitor. It very well may be found available under the brand name Lenvima. Lenvatinib has been endorsed for use in separated thyroid malignant growth, renal cell carcinoma, and hepatocellular carcinoma and as of late for the therapy of endometrial disease. https://otherarticles.com/health/diseases-and-conditions/349414-an-outline-of-the-expense-of-lenvatinib.html